Therapeutic potential of hydroxychloroquine on serum B-cell activating factor belonging to the tumor necrosis factor family (BAFF) in rheumatoid arthritis patients

Bulletin of Faculty of Pharmacy, Cairo University - Tập 52 - Trang 37-43 - 2014
Amina A. Mahdy1, Hala A. Raafat2, Hussein S. El-Fishawy3, Tamer A. Gheita2
1Pharmacology and Toxicology Department, Faculty of Pharmacy, Cairo University, Egypt
2Rheumatology Department, Faculty of Medicine, Cairo University, Egypt
3Internal Medicine Department, Faculty of Medicine, Cairo University, Egypt

Tài liệu tham khảo

Vallerskog, 2006, Differential effects on BAFF and APRIL levels in rituximab-treated patients with systemic lupus erythematosus and rheumatoid arthritis, Arthritis Res. Ther., 8, R167, 10.1186/ar2076

Agarwal, 2011, Biologic agents in rheumatoid arthritis: an update for managed care professionals, J. Manag. Care Pharm., 17, S14, 10.18553/jmcp.2011.17.s9-b.S14

Braun, 2011, Methotrexate: optimizing the efficacy in rheumatoid arthritis, Ther. Adv. Musculoskelet. Dis., 3, 151, 10.1177/1759720X11408635

Bosello, 2007, BAFF and rheumatic autoimmune disorders: implications for disease management and therapy, Int. J. Immunopathol. Pharmacol., 20, 1, 10.1177/039463200702000101

Sun, 2008, BAFF-targeting therapy, a promising strategy for treating autoimmune diseases, Eur. J. Pharmacol., 597, 1, 10.1016/j.ejphar.2008.08.027

Jin, 2013, Belimumab – an anti-BLyS human monoclonal antibody for rheumatoid arthritis, Expert Opin. Biol. Ther., 13, 315, 10.1517/14712598.2012.758248

Lee, 2013, B cell activating factor-dependent expression of vascular endothelial growth factor in MH7A human synoviocytes stimulated with tumor necrosis factor-α, Int. Immunopharmacol., 17, 142, 10.1016/j.intimp.2013.04.026

Gheita, 2012, Elevated BAFF (BLyS) and APRIL in Juvenile idiopathic arthritis patients: relation to clinical manifestations and disease activity, Joint Bone Spine, 79, 285, 10.1016/j.jbspin.2011.05.020

Mackay, 2003, BAFF and APRIL: a tutorial on B cell survival, Annu. Rev. Immunol., 21, 231, 10.1146/annurev.immunol.21.120601.141152

Fawzy, 2011, Serum BAFF level and its correlations with various disease parameters in patients with systemic sclerosis and systemic lupus erythematosus, Egypt. Rheumatol., 33, 45, 10.1016/j.ejr.2010.12.001

Gheita, 2013, Serum level of APRIL/BLyS in Behçet’s disease patients: clinical significance in uveitis and disease activity, Mod. Rheumatol., 23, 542, 10.3109/s10165-012-0694-x

Allison, 2000, Immunosuppressive drugs: the first 50years and a glance forward, Immunopharmacology, 47, 63, 10.1016/S0162-3109(00)00186-7

Sellam, 2011, B cell activation biomarkers as predictive factors for the response to rituximab in rheumatoid arthritis: a six-month, national, multicenter, open-label study, Arthritis Rheum., 63, 933, 10.1002/art.30233

Blüml, 2013, B-cell targeted therapeutics in clinical development, Arthritis Res. Ther., 15, S4, 10.1186/ar3906

Aletaha, 2010, Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League against rheumatism collaborative initiative, Arthritis Rheum., 62, 2569, 10.1002/art.27584

Prevoo, 1995, Modified disease activity scores that include twenty-eight-joint counts: development and validation in a prospective longitudinal study of patients with rheumatoid arthritis, Arthritis Rheum., 38, 44, 10.1002/art.1780380107

Bosello, 2008, Concentrations of BAFF correlate with autoantibody levels, clinical disease activity, and response to treatment in early rheumatoid arthritis, J. Rheumatol., 35, 1256

La, 2008, B lymphocyte stimulator expression in patients with rheumatoid arthritis treated with tumour necrosis factor alpha antagonists: differential effects between good and poor clinical responders, Ann. Rheum. Dis., 67, 1132, 10.1136/ard.2007.079954

Moura, 2011, Cytokine pattern in very early rheumatoid arthritis favours B-cell activation and survival, Rheumatology (Oxford), 50, 278, 10.1093/rheumatology/keq338

Moura, 2013, BAFF and TACI gene expression are increased in patients with untreated very early rheumatoid arthritis, J. Rheumatol., 40, 1293, 10.3899/jrheum.121110

Gottenberg, 2009, Markers of B-lymphocyte activation are elevated in patients with early rheumatoid arthritis and correlated with disease activity in the ESPOIR cohort, Arthritis Res. Ther., 11, R114, 10.1186/ar2773

Vincent, 2013, The BAFF/APRIL system: emerging functions beyond B cell biology and autoimmunity, Cytokine Growth Factor Rev., 24, 203, 10.1016/j.cytogfr.2013.04.003

Geng, 2012, Comparative study on the level of B lymphocyte stimulator (BlyS) and frequency of lymphocytes between sero-negative and sero-positive rheumatoid arthritis patients, Int. J. Rheum. Dis., 15, 478, 10.1111/j.1756-185X.2012.01814.x

Gümüş, 2013, Gingival crevicular fluid and serum levels of APRIL, BAFF and TNF-alpha in rheumatoid arthritis and osteoporosis patients with periodontal disease, Arch. Oral Biol., 58, 1302, 10.1016/j.archoralbio.2013.07.010

Mumcu, 2013, Salivary and serum B-cell activating factor (BAFF) levels after hydroxychloroquine treatment in primary Sjögren’s syndrome, Oral Health Prev. Dent., 11, 229

Yavuz, 2011, Hydroxychloroquine improves dry eye symptoms of patients with primary Sjogren’s syndrome, Rheumatol. Int., 31, 1045, 10.1007/s00296-010-1415-4

Gottenberg, 2006, No evidence for an association between the −871 T/C promoter polymorphism in the B-cell-activating factor gene and primary Sjögren’s syndrome, Arthritis Res. Ther., 8, R30, 10.1186/ar1884

Sibilia, 2008, Systemic lupus erythematosus: news and therapeutic perspectives, Presse Med., 37, 444, 10.1016/j.lpm.2007.11.011

Ramos-Barrón, 2009, Leflunomide derivative FK778 inhibits production of antibodies in an experimental model of alloreactive T–B cell interaction, Exp. Clin. Transplant., 7, 218

Siemasko, 1998, Inhibition of JAK3 and STAT6 tyrosine phosphorylation by the immunosuppressive drug leflunomide leads to a block in IgG1 production, J. Immunol., 160, 1581, 10.4049/jimmunol.160.4.1581

Smolen, 1999, Efficacy and safety of leflunomide compared with placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial, Eur. Leflunomide Study Group Lancet., 353, 259

Manda, 2009, Preliminary study on the immunologic background of good clinical outcome in rheumatoid arthritis patients after 1month therapy with leflunomide, Rheumatol. Int., 29, 937, 10.1007/s00296-008-0802-6

Genovese, 2013, A phase 2 dose-ranging study of subcutaneous tabalumab for the treatment of patients with active rheumatoid arthritis and an inadequate response to methotrexate, Ann. Rheum. Dis., 72, 1453, 10.1136/annrheumdis-2012-202864

Genovese, 2013, Tabalumab in rheumatoid arthritis patients with an inadequate response to methotrexate and naive to biologic therapy: a phase II, randomized, placebo-controlled trial, Arthritis Rheum., 65, 880, 10.1002/art.37820

Ferraccioli, 2012, Biomarkers of good EULAR response to the B cell depletion therapy in all seropositive rheumatoid arthritis patients: clues for the pathogenesis, PLoS One, 7, e40362, 10.1371/journal.pone.0040362

Thông tin
Thông tin xuất bản

Bulletin of Faculty of Pharmacy, Cairo University

Tập 52

37-43

Thông tin tác giả